Nature of the Event
Fortis Healthcare Limited has submitted a regulatory intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure concerns a corporate action by its material subsidiary, Agilus Diagnostics Limited.
Key Development
The Board of Directors of Agilus Diagnostics Limited approved an intra-group restructuring in its meeting held on August 5, 2026, which concluded at 04:30 PM. The restructuring involves a merger of its wholly-owned subsidiaries, Agilus Pathlabs Private Limited and DDRC Agilus Pathlabs Limited, into Agilus Diagnostics Limited. This will be effected through a Scheme of Arrangement.
Approvals and Conditions
The Scheme is subject to approval from the jurisdictional National Company Law Tribunals (NCLTs) and any other relevant authorities that may be required. It is also subject to approval from the members and creditors of the companies involved.
Financial and Consideration Details
As the Scheme is an intra-group restructuring involving the merger of wholly-owned subsidiaries, no consideration will be payable pursuant to the Scheme.